Details of the Drug

General Information of Drug (ID: DM376WT)

Drug Name
NKTR 214
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Sarcoma 2A60-2C35 Phase 2 [2]
Bladder cancer 2C94 Phase 1/2 [3]
Colorectal cancer 2B91.Z Phase 1/2 [3]
Renal cell carcinoma 2C90 Phase 1/2 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
⏷ Show the Full List of Indication(s)
Cross-matching ID
TTD ID
D02QQE
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor beta (IL2RB) TT9721Y IL2RB_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 7.52E-01 -0.06 -1.11
Interleukin 2 receptor beta (IL2RB) DTT IL2RB 1.96E-01 -4.70E-03 -0.01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03635983) A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)